Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Aufreinigung
This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This IRF9 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 75-104 amino acids from the N-terminal region of human IRF9.
IRF9
Reaktivität: Human
WB, IF
Wirt: Maus
Polyclonal
unconjugated
Applikationshinweise
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:10~50
For IF starting dilution is: 1:10~50
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.28 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
IRF9 is a transcription regulatory factor that mediates signaling by type I IFNs (IFN-alpha and IFN-beta). Following type I IFN binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize, associate with IRF9/ISGF3G to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of interferon stimulated genes, which drive the cell in an antiviral state.